Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Director Acquires $10,800.00 in Stock

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Director Aron Shapiro acquired 3,000 shares of the stock in a transaction on Tuesday, September 10th. The stock was bought at an average cost of $3.60 per share, with a total value of $10,800.00. Following the completion of the transaction, the director now owns 3,000 shares in the company, valued at $10,800. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Kiora Pharmaceuticals Stock Up 1.1 %

Shares of KPRX opened at $3.66 on Friday. The company has a 50 day moving average price of $3.96 and a 200-day moving average price of $4.87. Kiora Pharmaceuticals, Inc. has a fifty-two week low of $3.00 and a fifty-two week high of $8.98.

Kiora Pharmaceuticals (NASDAQ:KPRX) last announced its quarterly earnings results on Friday, August 9th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.95) by $0.42. The company had revenue of $0.02 million during the quarter. As a group, sell-side analysts anticipate that Kiora Pharmaceuticals, Inc. will post 1.17 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kiora Pharmaceuticals

An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC acquired a new stake in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals comprises 0.8% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 16th largest holding. Stonepine Capital Management LLC owned approximately 6.86% of Kiora Pharmaceuticals at the end of the most recent quarter. 76.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on KPRX shares. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Kiora Pharmaceuticals in a research note on Thursday, August 22nd. Maxim Group upgraded Kiora Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, June 13th.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.